-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Junshi Biotech announced that the company’s self-developed anti-PD-1 monoclonal antibody drug teriprizumab combined with chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (JUPITER).
-06 Study) In the interim analysis, the Independent Data Monitoring Committee (IDMC) determined that the two main research endpoints, Progression-Free Survival (PFS) and Overall Survival (OS), reached the superiority threshold preset by the protocol
.
Junshi Bio will communicate with regulatory authorities in the near future to submit listing applications
Esophageal cancer is a malignant tumor that originates in the epithelium of the esophageal mucosa and is one of the most common tumors in the world
.
Relevant data show that in 2020, esophageal cancer is the seventh most common malignant tumor and the sixth leading cause of cancer death in the world
The JUPITER-06 study (NCT03829969) is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study, which aims to compare the effects of teriprizumab combined with paclitaxel/cisplatin with placebo combined with paclitaxel/cisplatin.
Efficacy and safety of first-line treatment for advanced esophageal squamous cell carcinoma
.
According to the results of the mid-term analysis of the JUPITER-06 study, the Independent Data Monitoring Committee (IDMC) determined that the two main research endpoints of the study, Progression-Free Survival (PFS) and Overall Survival (OS), both reached the superiority threshold preset by the protocol.
